Huilan Yao

1.5k total citations
9 papers, 600 citations indexed

About

Huilan Yao is a scholar working on Molecular Biology, Genetics and Hematology. According to data from OpenAlex, Huilan Yao has authored 9 papers receiving a total of 600 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 4 papers in Genetics and 4 papers in Hematology. Recurrent topics in Huilan Yao's work include Epigenetics and DNA Methylation (3 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers) and Acute Myeloid Leukemia Research (2 papers). Huilan Yao is often cited by papers focused on Epigenetics and DNA Methylation (3 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers) and Acute Myeloid Leukemia Research (2 papers). Huilan Yao collaborates with scholars based in United States, Czechia and Greece. Huilan Yao's co-authors include Gail Mandel, Marc A. Kerenyi, Jinchun Chen, Stuart H. Orkin, Yawu Wang, Guo‐Qiang Chen, Qiong Wu, Jennifer J. Trowbridge, Jian Xu and Serena Hou and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and PLoS ONE.

In The Last Decade

Huilan Yao

9 papers receiving 588 citations

Peers

Huilan Yao

MB

PHYSI

BIOCH

GENET

BIOMA

Erica Sellink Netherlands

Emine Korkmaz Türkiye

Eva Costanzi Italy

Irina Kozhukharova Russia

Hao Daniel Lin Singapore

Kai Fu United States

Dan Ma China

Viviana De Rosa Italy

Xingrong Yan China

Allie M. Sohn United States

Erica Sellink Netherlands

Huilan Yao

326 ×1.1

MB

95 ×0.6

PHYSI

48 ×0.3

BIOCH

39 ×0.3

GENET

4 ×0.0

BIOMA

Citations per year, relative to Huilan Yao Huilan Yao (= 1×) peers Erica Sellink

Countries citing papers authored by Huilan Yao

Since Specialization

Citations

This map shows the geographic impact of Huilan Yao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huilan Yao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huilan Yao more than expected).

Fields of papers citing papers by Huilan Yao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Huilan Yao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huilan Yao. The network helps show where Huilan Yao may publish in the future.

Co-authorship network of co-authors of Huilan Yao

This figure shows the co-authorship network connecting the top 25 collaborators of Huilan Yao. A scholar is included among the top collaborators of Huilan Yao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Huilan Yao. Huilan Yao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Delimpasi, Sosana, Meletios Α. Dimopoulos, Jan Štraub, et al.. (2024). Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma. American Journal of Hematology. 99(9). 1746–1756. 3 indexed citations

2.

Delimpasi, Sosana, Meletios Α. Dimopoulos, Jan Štraub, et al.. (2022). Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study. Blood. 140(Supplement 1). 9995–9997. 1 indexed citations

3.

Werf, Inge van der, Anna Wojtuszkiewicz, Huilan Yao, et al.. (2021). SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia. Leukemia. 35(9). 2698–2702. 8 indexed citations

4.

Yao, Huilan, Devorah C. Goldman, Guang Fan, Gail Mandel, & William H. Fleming. (2015). The Corepressor Rcor1 Is Essential for Normal Myeloerythroid Lineage Differentiation. Stem Cells. 33(11). 3304–3314. 16 indexed citations

5.

McGann, James C., Jon A. Oyer, Saurabh Garg, et al.. (2014). Polycomb- and REST-associated histone deacetylases are independent pathways toward a mature neuronal phenotype. eLife. 3. e04235–e04235. 33 indexed citations

6.

Yao, Huilan, Devorah C. Goldman, Tamilla Nechiporuk, et al.. (2014). Corepressor Rcor1 is essential for murine erythropoiesis. Blood. 123(20). 3175–3184. 23 indexed citations

7.

Xu, Jian, Daniel E. Bauer, Marc A. Kerenyi, et al.. (2013). Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A. Proceedings of the National Academy of Sciences. 110(16). 6518–6523. 176 indexed citations

8.

Toh, Shen Yon, Jingyi Gong, Guoli Du, et al.. (2008). Up-Regulation of Mitochondrial Activity and Acquirement of Brown Adipose Tissue-Like Property in the White Adipose Tissue of Fsp27 Deficient Mice. PLoS ONE. 3(8). e2890–e2890. 219 indexed citations

9.

Wang, Yawu, et al.. (2004). Biodegradation studies of poly(3-hydroxybutyrate-co-3-hydroxyhexanoate). Polymer Degradation and Stability. 85(2). 815–821. 121 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact